Major P - Search Results

1

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.

Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Lipton A, et al. Among authors: major p. Oncologist. 2007 Sep;12(9):1035-43. doi: 10.1634/theoncologist.12-9-1035. Oncologist. 2007. PMID: 17914073 Free article. Clinical Trial.

2

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.

Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE. Hirsh V, et al. Among authors: major pp. J Thorac Oncol. 2008 Mar;3(3):228-36. doi: 10.1097/JTO.0b013e3181651c0e. J Thorac Oncol. 2008. PMID: 18317064 Free article. Clinical Trial.

3

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.

Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE. Lipton A, et al. Among authors: major p. Cancer. 2008 Jul 1;113(1):193-201. doi: 10.1002/cncr.23529. Cancer. 2008. PMID: 18459173 Free article.

4

Zoledronic acid use in cancer patients: more than just supportive care?

Coleman R, Cook R, Hirsh V, Major P, Lipton A. Coleman R, et al. Among authors: major p. Cancer. 2011 Jan 1;117(1):11-23. doi: 10.1002/cncr.25529. Cancer. 2011. PMID: 21235033 Free article. Review.

5

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R. Coleman RE, et al. Among authors: major p. J Clin Oncol. 2005 Aug 1;23(22):4925-35. doi: 10.1200/JCO.2005.06.091. Epub 2005 Jun 27. J Clin Oncol. 2005. PMID: 15983391

6

Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma.

Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E, Berenson JR. Lipton A, et al. Among authors: major p. Clin Lymphoma Myeloma. 2007 Mar;7(5):346-53. doi: 10.3816/CLM.2007.n.011. Clin Lymphoma Myeloma. 2007. PMID: 17562244 Review.

7

Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.

Major PP, Cook R. Major PP, et al. Am J Clin Oncol. 2002 Dec;25(6 Suppl 1):S10-8. doi: 10.1097/00000421-200212001-00003. Am J Clin Oncol. 2002. PMID: 12562046 Review.

8

Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.

Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE. Major PP, et al. BMC Cancer. 2009 Aug 6;9:272. doi: 10.1186/1471-2407-9-272. BMC Cancer. 2009. PMID: 19660124 Free PMC article. Clinical Trial.

9

Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials.

Coleman RE, Lipton A, Costa L, Cook RJ, Lee KA, Saad F, Brown JE, Terpos E, Major PP, Kohno N, Smith M, Body JJ. Coleman RE, et al. Among authors: major pp. J Bone Oncol. 2013 Feb 9;2(2):70-6. doi: 10.1016/j.jbo.2013.01.002. eCollection 2013 Jun. J Bone Oncol. 2013. PMID: 26909273 Free PMC article.

10

Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.

Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, Major P. Coleman R, et al. Among authors: major p. Cancer Treat Rev. 2008 Nov;34(7):629-39. doi: 10.1016/j.ctrv.2008.05.001. Epub 2008 Jun 24. Cancer Treat Rev. 2008. PMID: 18579314 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

982 results

Search Page